Cryo-Cell International, Inc. (CCEL)
CCELAMEXMisc Health and Biotechnology Services
$4.87
-0.0450 (-0.92%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $39.75m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.72 to $5.45
- Average volume
- –
- Previous close
- $4.92
Earnings
Next report
Financials
| Quarter | Nov 2025 | Feb 2026 | May 2026 | Aug 2026 |
|---|---|---|---|---|
| Revenue | $7.84m | $7.68m | $7.78m | $7.82m |
| Gross profit | $6.11m | $6.03m | $6.10m | $6.21m |
| Operating income | -$3.97m | $765.0k | $1.20m | $2.19m |
| Net income | -$3.82m | $47.0k | $555.0k | $1.27m |
Last four quarters: revenue $31.13m, margin -6.3%, free cash flow $4.65m
News
5 latest- Cryo-Cell International, Inc. Announces Voting Results of October 27, 2026 Annual Meeting of StockholdersFintel · Oct 29, 2026
- Cryo-Cell International Inc Q3 Profit Drops RTTNews · Oct 15, 2025
- Friday 9/12 Insider Buying Report: CCEL, AROWBNK Invest · Sep 12, 2025
- Thursday 8/28 Insider Buying Report: D, CCELBNK Invest · Aug 28, 2025
- $CCEL Earnings Preview: Recent $CCEL Insider Trading, Hedge Fund Activity, and MoreQuiver Quantitative · Apr 14, 2025
The company
Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. The Company, together with its global affiliates, stores more than 250,000 cord blood and cord tissue specimens for the exclusive benefit of newborn babies and their families. In addition to its private bank, Cryo-Cell International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell's public bank has provided cord blood for more than 900 transplants. Cryo-Cell's facility is FDA-registered, cGMP-/cGTP-compliant, and licensed in all states requiring licensure. In addition to AABB accreditation as a cord blood facility, Cryo-Cell was the first U.S. private (family-use) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell holds exclusive rights to PrepaCyte-CB, the industry's most advanced cord blood processing technology.
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- Exchange
- AMEX
- Region
- North America
- Website
- cryo-cell.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.